How big is DMK Pharmaceuticals Corp.?

As of Jun 18, DMK Pharmaceuticals Corp. has a market capitalization of 0.00, with net sales of 3.62 million and a net profit of -21.15 million over the latest four quarters. As of Dec 22, shareholder's funds are reported at -0.65 million, and total assets amount to 10.93 million.

As of Jun 18, DMK Pharmaceuticals Corp. has a market capitalization of 0.00, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 3.62 million, while the sum of Net Profit for the same period is -21.15 million.<BR><BR>As of Dec 22, the Shareholder's Funds are reported at -0.65 million, and the Total Assets amount to 10.93 million.

Who are in the management team of DMK Pharmaceuticals Corp.?

As of March 2022, the management team of DMK Pharmaceuticals Corp. includes Mr. Richard Williams (Independent Chairman), Dr. Dennis Carlo (CEO), Mr. David Marguglio (Chief Business Officer), Mr. Howard Birndorf (Independent Director), and Ms. Roshawn Blunt (Independent Director). They oversee the company's operations and strategic direction.

As of March 2022, the management team of DMK Pharmaceuticals Corp. includes the following individuals:<BR><BR>- Mr. Richard Williams, Independent Chairman of the Board, Consultant<BR>- Dr. Dennis Carlo, President, Chief Executive Officer, Director<BR>- Mr. David Marguglio, Senior Vice President, Chief Business Officer and Director<BR>- Mr. Howard Birndorf, Independent Director, Consultant<BR>- Ms. Roshawn Blunt, Independent Director, Consultant<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Should I buy, sell or hold DMK Pharmaceuticals Corp.?

Is DMK Pharmaceuticals Corp. overvalued or undervalued?

As of July 8, 2024, DMK Pharmaceuticals Corp. is considered overvalued and has moved to a "does not qualify" valuation grade due to a P/E ratio of 0.00, a negative EV to Sales ratio of -1.82, and a 100% decline in stock value over the past year, contrasting sharply with the S&P 500's 17.14% return.

As of 8 July 2024, the valuation grade for DMK Pharmaceuticals Corp. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company appears to be overvalued, particularly given its current P/E ratio of 0.00 and negative EV to Sales ratio of -1.82, which suggest that the market does not assign any value to its earnings or sales. Additionally, the EV to EBITDA ratio stands at 0.36, further highlighting the lack of investor confidence in the company's profitability.<BR><BR>In comparison to peers, DMK Pharmaceuticals Corp. shows a stark contrast with Inhibikase Therapeutics, which has an EV to EBITDA of -0.79, and Aileron Therapeutics, which has an EV to EBITDA of -1.05, both indicating challenges in their valuations as well. Notably, DMK Pharmaceuticals has experienced a 100% decline in stock value over the past year, while the S&P 500 has returned 17.14%, reinforcing the notion that DMK is not performing well relative to broader market trends.

Is DMK Pharmaceuticals Corp. technically bullish or bearish?

As of June 23, 2025, DMK Pharmaceuticals Corp. shows a mildly bearish trend with mixed signals, including a bearish monthly RSI and a significant 1-year decline of 100%, contrasting with the S&P 500's 17.14% return.

As of 23 June 2025, the technical trend for DMK Pharmaceuticals Corp. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some short-term positive momentum. However, the monthly RSI is bearish, indicating weakness over a longer time frame. Overall, the mixed signals lead to a mildly bearish outlook. The company has experienced a significant decline, with a 1-year return of -100% compared to the S&P 500's 17.14% return.